Study shows that sodium-glucose cotransporter-2 inhibitor use is linked to decreased risk for flare in adults with gout and type 2 diabetes
A recent study published in the Annals of Internal Medicine found that sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a decreased risk for recurrent gout flares, gout-related emergency department visits, and gout-related hospitalizations, as well as cardiovascular benefits. In a propensity score-matched cohort research, Dr. Natalie McCormick from Massachusetts General Hospital in Boston, and colleagues … Read more